MAPT and Alzheimer disease: The clinical symptoms of AD are driven by the accumulation of amyloid beta (Aβ) plaques and neurofibrillary tau tangles (NFTs), neuroinflammation, and neuronal loss (Scheltens et al. 2021; Alzheimer's Association 2025).